ABSTRACT
OBJECTIVE: To investigate therapeutic efficacy of Goserelin acetate sustained-release implants combined with bicalutamide in the treatment of elderly (≥70 years old) prostate cancer patients, and its effects on cognitive function and short-term survival rate. METHODS: A total of 56 prostate cancer patients treated in our hospital from Nov. 2014 to Nov. 2016 were divided into observation group and control group according to random number table, with 28 cases in each group. Observation group was given maximal androgen blokage (MAB) treatment which was Goserelin acetate sustained-release implant (subcutaneous injection of abdominal wall, 3. 6 mg/ times, once) combined with Bicalutamide tablet (orally, 50 mg/times, qd). Control group received surgical castration, and then was given docetaxel (intravenous dripping on 1st day) combined with Prednisone acetate tablets (lst-21st day, orally, 5 mg/time, bid) after surgery for adjuvant therapy. Treatment course of 2 groups lasted for 3 weeks, and all patients were followed up for 12 months. Clinical efficacy, Montreal cognitive function assessment table (MoCA) score, serum prostate specific antigen (PSA) levels and 12-month survival rate were observed in 2 groups. RESULTS: The total response rate of observation group was significantly higher than that of control group, with statistical significance (P<0. 05). Before treatment, there was no statistical significance in MoCA score and serum PSA levels between 2 groups (P>0. 05). After treatment, MoCA scores of 2 groups were decreased significantly, and the observation group was higher than the control group, with statistical significance (P<0. 05). 6 and 12 months after treatment, serum PSA levels of 2 groups were decreased significantly, and the observation group was significantly lower than the control group, with statistical significance (P<0. 05); 12-month survival rate of observation group (92. 86％) was significantly higher than that of control group (64. 29％), with statistical significance (P< 0. 05). CONCLUSIONS: Nonsteroidal anti-androgen drugs show significant therapeutic efficacy for elderly prostate cancer, reduce cognitive function damage, improve serum PSA levels, therapeutic efficacy and short-term survival rate.
ABSTRACT
Objective In recent years,as people have attached importance to the application of regional chemotherapy in the surgery of advanced gastric cancer,the research of fluorouracil sustained release implant,a regional chemotherapeutic drug,is on the increase.Fluorouracil sustained release implant is a new anti-carcinogen combined with fluorouracil,a conventional chemotherapeutic drug,through polymeric scaffolds and rete technology.It can be implanted into cancerous lesion area,as its slow-releasing potential and targeting property will give full play to the antitumor effect of fluorouracil,which can decrease the rate of local recurrence and metastasis of gastric cancer and prolong the life span of the patients.Based on the study of the researches on fluorouracil sustained release implant,a summary was made from different perspectives: basic medicine,pharmacy and clinical medicine.It may have reference value for clinical application and further study.
ABSTRACT
OBJECTIVE: To study the factors affecting the in vitro release rate of doxorubicin hydrochloride sustained release implants for glioma to provide information for pharmacodynamic evaluation in animals. METHODS: The implants were prepared by incorporating doxorubicin hydrochloride into poly(lactide-co-glycolide) (PLGA) matrix. The in vitro release rate of the implants was determined by UV. The copolymer ratio and molecular weight (Mw) of PLGA, and the drug loading were examined to study their effects on the in vitro release rate of the implants. RESULTS: The release rate of 10% drug-loaded implants was greater than that of 5% drug-loaded ones, and it was enhanced by an increase in the proportion of copolymerized glycollic acid in PLGA. The cumulative release rate of the implants with LA-GA ratio of 50: 50 was 90% at 35 d, while that of the implants with LA-GA ratio of 75: 25 was only about 60%. The molecular weight of PLGA was inversely proportional to the release rate of the implants. The release rate of the implants with Mw of 20748 was greater than that with Mw of 30834. CONCLUSION: The factors affecting the in vitro release rate of the implants include the copolymer ratio of PLGA, the molecular weight of PLGA and the drug loading, among which the copolymer ratio and molecular weight of PLGA are the major factors. The drug release rate of the implants can be well controlled by regulating the copolymer ratio and molecular weight of PLGA matrix. Copyright 2012 by the Chinese Pharmaceutical Association.